Results 171 to 180 of about 9,118,901 (248)

Metabolic Nanomedicine Reprograms Mesenchymal Stem Cells for Durable Exosome‐Mediated Immunomodulation

open access: yesExploration, EarlyView.
Prolonged inflammatory stress depletes NAD+ in mesenchymal stem cells, driving functional exhaustion and weakening their survival and immune‐regulating activity. We developed an NAD+‐delivering nanomedicine that restores cellular metabolism and improves therapeutic efficacy in colitis.
Jinfeng Chen   +9 more
wiley   +1 more source

Implantable electrochemical sensors for continuous blood monitoring

open access: yesFlexMat, EarlyView.
Implantable electrochemical sensors enable direct, in situ, and continuous blood monitoring, shifting diagnosis from population‐based averages to dynamic, individualized analysis. This review systematically examines the influence of the unique blood properties on sensor design.
Kuangyi Zou   +3 more
wiley   +1 more source

Engineering an artificial trachea: Quantitative benchmarks and modular strategies for mechanics, epithelialization, and vascular integration

open access: yesFlexMat, EarlyView.
In this work, we first examine the limitations of surgical repair and stenting, including migration, granulation, mucus plugging, and infection. We then translate these failures into engineering constraints involving geometry, mechanics, fixation, degradation, junctional stress, and remodeling.
Yiwei Xu   +6 more
wiley   +1 more source

Oral Bacterial Extracellular Vesicles as Systemic Messengers: A Mouth–Gut–Systemic Axis Paradigm

open access: yesGut Medicine, EarlyView.
ABSTRACT Oral microbiome dysbiosis not only associated with localized periodontal disease but also with multiple systemic diseases, including cardiovascular disease, diabetes mellitus, Alzheimer's disease, rheumatoid arthritis, and cancer. However, the efficiency with which intact viable bacteria cross biological barriers to reach distant organs is ...
Yaping Huang   +5 more
wiley   +1 more source

Craniofacial Resection for Advanced Cutaneous Squamous Cell Carcinoma: Results From the 2nd International Collaborative Case‐Series

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Robust outcome data for anterior skull base cutaneous squamous cell carcinoma (cSCC) are limited, particularly as emerging therapies reshape management. We evaluated survival and prognostic factors following craniofacial resection. Methods Retrospective multi‐institutional case‐series (1995–2015) of patients who underwent skull base
Michael J. C. Schachtel   +52 more
wiley   +1 more source

Viability of Tumor Cells in Bone Dust: Implications for Oncologic Skull Base Surgery

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Head and neck tumors with skull base involvement may require drilling of tumor infiltrated bone. We hypothesize that bone dust generated during this process contains viable tumor cells that may seed the surgical field. Methods Tumors with gross bone invasion were drilled, and dust was collected for H&E, cell viability analysis, and ...
Kelly Bridgham   +14 more
wiley   +1 more source

Aggressive Mandibular Squamous Cell Carcinoma Mimicking Periodontal Disease in a Non‐Transplanted Patient With Fanconi Anemia

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Fanconi anemia (FA) is associated with markedly increased risk for early‐onset oral squamous cell carcinoma (OSCC). Methods We report an aggressive mandibular squamous cell carcinoma in a 26‐year‐old non‐transplanted woman with FA initially interpreted as localized periodontal disease adjacent to a tongue leukoplakia.
Cassius Carvalho Torres‐Pereira   +4 more
wiley   +1 more source

Early Chidamide Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in High‐Risk Myeloid Malignancies: A Prospective Cohort With Time‐Dependent External‐Control Analysis

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Chidamide is an oral histone deacetylase inhibitor whose use as early maintenance after allogeneic hematopoietic stem cell transplantation (HSCT) remains insufficiently defined. This prospective single‐center Phase 1/2 cohort included all 47 patients enrolled and treated by March 31, 2026.
Haonan Yang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy